XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB)
NASDAQ:XTLB
Want to see XTLB full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/ADate:―
No summary available
Positive Factors
Pipeline Development
The company's focus on developing therapeutic candidates for unmet medical needs in autoimmune diseases and oncology indicates a strong potential for future growth and market relevance, as successful drug development can lead to significant revenue streams from licensing and sales.
Negative Factors
Negative Cash Flow
Persistent negative cash flow highlights liquidity challenges, limiting the company's ability to invest in growth opportunities and sustain operations without external funding, which could hinder long-term strategic objectives and financial stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline Development
The company's focus on developing therapeutic candidates for unmet medical needs in autoimmune diseases and oncology indicates a strong potential for future growth and market relevance, as successful drug development can lead to significant revenue streams from licensing and sales.
Read all positive factors
XTL Biopharmaceuticals Sponsored ADR (XTLB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.76M
Dividend YieldN/A
Average Volume (3M)98.27K
Price to Earnings (P/E)―
Beta (1Y)0.54
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.14
Shares Outstanding2,365,608
10 Day Avg. Volume49,384
30 Day Avg. Volume98,272
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.63
Price to Sales (P/S)7.57
P/FCF Ratio-2.04
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue17.78
Enterprise Value/Gross Profit67.39
Enterprise Value/Ebitda-10.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
XTL Biopharmaceuticals Sponsored ADR Business Overview & Revenue Model
Company Description
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the tr...
How the Company Makes Money
XTL Biopharmaceuticals generates revenue primarily through the development and commercialization of proprietary drug candidates targeting autoimmune diseases and cancer. The company may earn money from licensing agreements, milestone payments, and...
XTL Biopharmaceuticals Sponsored ADR Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 451.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.00K | 0.00 | -1.00K | -1.00K | -1.00K |
| EBITDA | -930.00K | -764.00K | -879.00K | -1.03M | -947.00K |
| Net Income | -1.03M | -1.78K | -1.35M | 435.00K | -782.00K |
Balance Sheet | |||||
| Total Assets | 8.55M | 2.43M | 4.19M | 6.62M | 6.50M |
| Cash, Cash Equivalents and Short-Term Investments | 1.14M | 2.01M | 3.72M | 6.13M | 6.04M |
| Total Debt | 138.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 3.12M | 206.00K | 187.00K | 1.28M | 254.00K |
| Stockholders Equity | 5.43M | 2.22M | 4.00M | 5.33M | 3.61M |
Cash Flow | |||||
| Free Cash Flow | -1.67M | -707.00K | -901.00K | -1.05M | -851.00K |
| Operating Cash Flow | -1.62M | -707.00K | -901.00K | -1.05M | -850.00K |
| Investing Cash Flow | -844.00K | 41.00K | 36.00K | 8.00K | 32.00K |
| Financing Cash Flow | 1.45M | 0.00 | 0.00 | 385.00K | 0.00 |
XTL Biopharmaceuticals Sponsored ADR Technical Analysis
Negative
2.45
Price Trends
2.87
Negative
3.09
Negative
4.16
Negative
Market Momentum
-0.10
Negative
45.41
Neutral
41.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XTLB, the sentiment is Negative. The current price of 2.45 is below the 20-day moving average (MA) of 2.46, below the 50-day MA of 2.87, and below the 200-day MA of 4.16, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 45.41 is Neutral, neither overbought nor oversold. The STOCH value of 41.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XTLB.
XTL Biopharmaceuticals Sponsored ADR Risk Analysis
XTL Biopharmaceuticals Sponsored ADR disclosed 38 risk factors in its most recent earnings report. XTL Biopharmaceuticals Sponsored ADR reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
XTL Biopharmaceuticals Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $5.76M | -5.14 | ― | ― | ― | ― | |
54 Neutral | $99.25M | -1.26 | -55.75% | ― | ― | 39.03% | |
48 Neutral | $17.30M | -4.62 | -59.29% | ― | -82.35% | -34713.73% | |
48 Neutral | $19.30M | -1.14 | -94.94% | ― | ― | 54.05% | |
48 Neutral | $21.67M | -1.15 | -112.05% | ― | ― | 99.89% | |
40 Underperform | $20.92K | 0.06 | -28.86% | ― | 159.68% | ― |
* Healthcare Sector Average
XTLB
XTL Biopharmaceuticals Sponsored ADR
2.30
-3.34
-59.22%
LPCN
Lipocine
2.31
-1.00
-30.21%
CARM
Carisma Therapeutics
0.01
-0.19
-94.95%
EDSA
Edesa Biotech
14.26
11.93
512.02%
COCP
Cocrystal Pharma
1.39
-0.12
-7.95%
ALLR
Allarity Therapeutics
1.37
0.17
14.17%
XTL Biopharmaceuticals Sponsored ADR Corporate Events
XTL Biopharmaceuticals Takes Major Impairment on The Social Proxy in First-Half 2025 Results
Dec 30, 2025
On December 30, 2025, XTL Biopharmaceuticals reported financial results for the six months ended June 30, 2025, highlighting a near-full write-down of its subsidiary The Social Proxy following a prolonged dispute with the unit’s former share...
XTL Biopharmaceuticals Faces Nasdaq Bid-Price Deficiency, Given Until June 2026 to Regain Compliance
Dec 29, 2025
On December 24, 2025, XTL Biopharmaceuticals announced it had received a Nasdaq notification, dated December 22, 2025, stating that the company’s American Depositary Shares had failed to meet the exchange’s minimum bid price requiremen...
XTL Biopharmaceuticals Faces Leadership Changes at Social Proxy Subsidiary
Dec 12, 2025
On December 11, 2025, XTL Biopharmaceuticals Ltd. announced the immediate resignation of Tal Klinger, CEO, and Roee Klinger, CTO, from Social Proxy Ltd., its wholly owned subsidiary. The company is currently assessing the management strategy for S...
XTL Biopharmaceuticals Announces CFO Transition Amid Strategic Appointments
Dec 5, 2025
On December 5, 2025, XTL Biopharmaceuticals announced the resignation of its Chief Financial Officer, Mr. Itay Weinstein, effective December 11, 2025. His departure was not due to any disagreements with the company. To fill the vacancy, the Board ...
XTL Biopharmaceuticals Announces Board Changes Following Resignation
Oct 23, 2025
On October 21, 2025, Doron Turjeman resigned from the Board of Directors of XTL Biopharmaceuticals Ltd. due to personal reasons, with no disagreements with the company. Subsequently, Noam Band, the CEO, was appointed to the board, potentially stre...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―